Peregrine Pharmaceuticals Inc (PPHM)

3.12
NASDAQ : Health Care
Prev Close 3.12
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.97 / 5.78
Avg Volume 308.20K
Exchange NASDAQ
Shares Outstanding 45.10M
Market Cap 140.70M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Stock Futures Rise as Irma Weakens to Tropical Storm and North Korea Is Quiet

Stock Futures Rise as Irma Weakens to Tropical Storm and North Korea Is Quiet

Stock futures are rising confidently.

Peregrine Pharmaceuticals Announces Appointment Of Roger J. Lias, Ph.D. As President Of Avid Bioservices

Peregrine Pharmaceuticals Announces Appointment Of Roger J. Lias, Ph.D. As President Of Avid Bioservices

Senior Executive with More Than Two Decades of CDMO Management Experience to Also Join Peregrine's Board of Directors

Peregrine Pharmaceuticals Announces First Patient Dosed In Phase II Clinical Trial Evaluating Bavituximab Treatment Combination In Patients With Newly Diagnosed Glioblastoma

Peregrine Pharmaceuticals Announces First Patient Dosed In Phase II Clinical Trial Evaluating Bavituximab Treatment Combination In Patients With Newly Diagnosed Glioblastoma

Trial is First of Three Planned Bavituximab Combination Studies Being Conducted as Part of Collaboration with National Comprehensive Cancer Network® (NCCN®)

Ronin Trading And SW Investment Management Respond To Recent Announcements By Peregrine Pharmaceuticals

Ronin Trading And SW Investment Management Respond To Recent Announcements By Peregrine Pharmaceuticals

Believe Incumbent Board Members are Responsible for Continued Destruction of Stockholder Value and Must be Held Accountable

Peregrine Provides Strategic Update

Peregrine Provides Strategic Update

Ronin Trading And SW Investment Management Issue Letter To Employees Of Peregrine Pharmaceuticals

Ronin Trading And SW Investment Management Issue Letter To Employees Of Peregrine Pharmaceuticals

Elaborate on Strategic Vision and Intentions with Respect to Peregrine

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 12% Yield Mark

In trading on Monday, shares of Peregrine Pharmaceuticals Inc's 10.50% Series E Convertible Preferred Stock were yielding above the 12% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $21.11 on the day. This compares to an average yield of 10.68% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

Peregrine Pharmaceuticals Announces Reverse Stock Split

Peregrine Pharmaceuticals Announces Reverse Stock Split

Common Stock to Trade on Split-Adjusted Basis Beginning at Opening of Market on July 10, 2017; Intended to Enable Continued Listing on the NASDAQ Capital Market

Peregrine Pharmaceuticals' Series E Preferred Stock Yield Pushes Past 12%

In trading on Thursday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 12% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $21.62 on the day. This compares to an average yield of 10.04% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

Peregrine Pharmaceuticals' Series E Preferred Stock Yield Pushes Past 13%

In trading on Wednesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 13% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $20.16 on the day. This compares to an average yield of 11.31% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

TheStreet Quant Rating: D (Sell)